Related Experiment Video
Updated: Aug 18, 2026
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
How tumors escape immune destruction and what we can do about it
1Department of Surgery, The Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC 27710, USA.
Abstract:
There is strong circumstantial evidence that tumor progression in cancer patients is controlled by the immune system. As will be detailed below, this conclusion is based on observations that tumor progression is often associated with secretion of immune suppressive factors and/or downregulation of MHC class I antigen presentation functions. The inference is that tumors must have elaborated strategies to circumvent an apparently effective immune response. Importantly, a tumor-specific immune response cannot be detected in most individuals. While this failure is in part technical, it also suggests that the magnitude of the immune responses to which tumors have to respond is low. This raises the concern, which is the underlying theme of this commentary, that a more robust immune response elicited by deliberate vaccination will exacerbate the rate of immune escape and nullify the potential benefits of immune-based therapies.
Insights
Cancer immune evasion strategies are suggested by tumor progression. However, robust immune responses from vaccination might worsen immune escape, negating cancer therapy benefits.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor progression in cancer patients is influenced by the immune system.
- Tumors employ immune suppressive factors and downregulate MHC class I presentation to evade immune detection.
- A detectable tumor-specific immune response is absent in most cancer patients.
Purpose of the Study:
- To explore the relationship between tumor progression and immune system control.
- To investigate the implications of tumor evasion strategies for cancer immunotherapy.
- To raise concerns about the potential negative impact of enhanced immune responses on therapeutic outcomes.
Main Methods:
- Review of existing evidence on tumor progression and immune evasion.
- Analysis of immune suppressive factors secreted by tumors.
- Evaluation of Major Histocompatibility Complex (MHC) class I antigen presentation in cancer.
Main Results:
- Tumor progression correlates with immune suppressive mechanisms.
- Downregulation of MHC class I presentation is a common tumor evasion strategy.
- Low magnitude of natural anti-tumor immune responses is observed in most patients.
Conclusions:
- Tumors develop sophisticated strategies to circumvent immune surveillance.
- The absence of a strong natural immune response suggests tumors adapt to minimal threats.
- Therapeutic strategies aiming to boost immune responses, like vaccination, may paradoxically accelerate immune escape and reduce treatment efficacy.
Related Concept Videos
01:40Cell-mediated Immune Responses
02:17The Tumor Microenvironment
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy